erbB in NSCLC as a molecular target: current evidences and future directions

A number of treatments have been developed for HER1, 2 and 3-driven non-small cell lung cancer (NSCLC), of which the most successful have been the epidermal growth factor receptor-tyrosine kinase inhibitors in HER1-mutant tumours resulting in highly improved progression-free survival. Human epiderma...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESMO Open
Asıl Yazarlar: Del Re, Marzia, Cucchiara, Federico, Petrini, Iacopo, Fogli, Stefano, Passaro, Antonio, Crucitta, Stefania, Attili, Ilaria, De Marinis, Filippo, Chella, Antonio, Danesi, Romano
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7443272/
https://ncbi.nlm.nih.gov/pubmed/32820012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000724
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller